All-trans retinoic acid with or without low dose cytosine arabinoside in acute promyelocytic leukemia. Report of 6 cases. 1987

M E Huang, and Y C Ye, and S R Chen, and J C Zhao, and L J Gu, and J R Cai, and L Zhao, and J X Xie, and Z X Shen, and Z Y Wang

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D002648 Child A person 6 to 12 years of age. An individual 2 to 5 years old is CHILD, PRESCHOOL. Children
D002675 Child, Preschool A child between the ages of 2 and 5. Children, Preschool,Preschool Child,Preschool Children
D003561 Cytarabine A pyrimidine nucleoside analog that is used mainly in the treatment of leukemia, especially acute non-lymphoblastic leukemia. Cytarabine is an antimetabolite antineoplastic agent that inhibits the synthesis of DNA. Its actions are specific for the S phase of the cell cycle. It also has antiviral and immunosuppressant properties. (From Martindale, The Extra Pharmacopoeia, 30th ed, p472) Ara-C,Arabinofuranosylcytosine,Arabinosylcytosine,Cytosine Arabinoside,Aracytidine,Aracytine,Cytarabine Hydrochloride,Cytonal,Cytosar,Cytosar-U,beta-Ara C,Ara C,Arabinoside, Cytosine,Cytosar U,beta Ara C
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D014212 Tretinoin An important regulator of GENE EXPRESSION during growth and development, and in NEOPLASMS. Tretinoin, also known as retinoic acid and derived from maternal VITAMIN A, is essential for normal GROWTH; and EMBRYONIC DEVELOPMENT. An excess of tretinoin can be teratogenic. It is used in the treatment of PSORIASIS; ACNE VULGARIS; and several other SKIN DISEASES. It has also been approved for use in promyelocytic leukemia (LEUKEMIA, PROMYELOCYTIC, ACUTE). Retinoic Acid,Vitamin A Acid,Retin-A,Tretinoin Potassium Salt,Tretinoin Sodium Salt,Tretinoin Zinc Salt,Vesanoid,all-trans-Retinoic Acid,beta-all-trans-Retinoic Acid,trans-Retinoic Acid,Acid, Retinoic,Acid, Vitamin A,Acid, all-trans-Retinoic,Acid, beta-all-trans-Retinoic,Acid, trans-Retinoic,Potassium Salt, Tretinoin,Retin A,Salt, Tretinoin Potassium,Salt, Tretinoin Sodium,Salt, Tretinoin Zinc,Sodium Salt, Tretinoin,Zinc Salt, Tretinoin,all trans Retinoic Acid,beta all trans Retinoic Acid,trans Retinoic Acid
D015470 Leukemia, Myeloid, Acute Clonal expansion of myeloid blasts in bone marrow, blood, and other tissue. Myeloid leukemias develop from changes in cells that normally produce NEUTROPHILS; BASOPHILS; EOSINOPHILS; and MONOCYTES. Leukemia, Myelogenous, Acute,Leukemia, Nonlymphocytic, Acute,Myeloid Leukemia, Acute,Nonlymphocytic Leukemia, Acute,ANLL,Acute Myelogenous Leukemia,Acute Myeloid Leukemia,Acute Myeloid Leukemia with Maturation,Acute Myeloid Leukemia without Maturation,Leukemia, Acute Myelogenous,Leukemia, Acute Myeloid,Leukemia, Myeloblastic, Acute,Leukemia, Myelocytic, Acute,Leukemia, Myeloid, Acute, M1,Leukemia, Myeloid, Acute, M2,Leukemia, Nonlymphoblastic, Acute,Myeloblastic Leukemia, Acute,Myelocytic Leukemia, Acute,Myelogenous Leukemia, Acute,Myeloid Leukemia, Acute, M1,Myeloid Leukemia, Acute, M2,Nonlymphoblastic Leukemia, Acute,Acute Myeloblastic Leukemia,Acute Myeloblastic Leukemias,Acute Myelocytic Leukemia,Acute Myelocytic Leukemias,Acute Myelogenous Leukemias,Acute Myeloid Leukemias,Acute Nonlymphoblastic Leukemia,Acute Nonlymphoblastic Leukemias,Acute Nonlymphocytic Leukemia,Acute Nonlymphocytic Leukemias,Leukemia, Acute Myeloblastic,Leukemia, Acute Myelocytic,Leukemia, Acute Nonlymphoblastic,Leukemia, Acute Nonlymphocytic,Leukemias, Acute Myeloblastic,Leukemias, Acute Myelocytic,Leukemias, Acute Myelogenous,Leukemias, Acute Myeloid,Leukemias, Acute Nonlymphoblastic,Leukemias, Acute Nonlymphocytic,Myeloblastic Leukemias, Acute,Myelocytic Leukemias, Acute,Myelogenous Leukemias, Acute,Myeloid Leukemias, Acute,Nonlymphoblastic Leukemias, Acute,Nonlymphocytic Leukemias, Acute

Related Publications

M E Huang, and Y C Ye, and S R Chen, and J C Zhao, and L J Gu, and J R Cai, and L Zhao, and J X Xie, and Z X Shen, and Z Y Wang
March 2001, Gan to kagaku ryoho. Cancer & chemotherapy,
M E Huang, and Y C Ye, and S R Chen, and J C Zhao, and L J Gu, and J R Cai, and L Zhao, and J X Xie, and Z X Shen, and Z Y Wang
July 1995, Leukemia,
M E Huang, and Y C Ye, and S R Chen, and J C Zhao, and L J Gu, and J R Cai, and L Zhao, and J X Xie, and Z X Shen, and Z Y Wang
March 1998, British journal of haematology,
M E Huang, and Y C Ye, and S R Chen, and J C Zhao, and L J Gu, and J R Cai, and L Zhao, and J X Xie, and Z X Shen, and Z Y Wang
January 2007, American journal of therapeutics,
M E Huang, and Y C Ye, and S R Chen, and J C Zhao, and L J Gu, and J R Cai, and L Zhao, and J X Xie, and Z X Shen, and Z Y Wang
March 1998, Leukemia & lymphoma,
M E Huang, and Y C Ye, and S R Chen, and J C Zhao, and L J Gu, and J R Cai, and L Zhao, and J X Xie, and Z X Shen, and Z Y Wang
May 2003, Leukemia & lymphoma,
M E Huang, and Y C Ye, and S R Chen, and J C Zhao, and L J Gu, and J R Cai, and L Zhao, and J X Xie, and Z X Shen, and Z Y Wang
October 2001, Oncogene,
M E Huang, and Y C Ye, and S R Chen, and J C Zhao, and L J Gu, and J R Cai, and L Zhao, and J X Xie, and Z X Shen, and Z Y Wang
January 1991, Nouvelle revue francaise d'hematologie,
M E Huang, and Y C Ye, and S R Chen, and J C Zhao, and L J Gu, and J R Cai, and L Zhao, and J X Xie, and Z X Shen, and Z Y Wang
February 1998, The New England journal of medicine,
M E Huang, and Y C Ye, and S R Chen, and J C Zhao, and L J Gu, and J R Cai, and L Zhao, and J X Xie, and Z X Shen, and Z Y Wang
October 1997, The New England journal of medicine,
Copied contents to your clipboard!